Drug Repurposing: Conversion of the Peripherally Restricted HIV Protease Inhibitor Amprenavir to Potent, Selective, and CNS-Penetrant Agonists for the Cannabinoid Receptor 2

Read full text
Authors: Daniel H. Haymer, Renn A. Duncan, Alice L. Rodriguez, Allie Han, Richard J. Lindsay, N. Kithmini Wijesiri, Analisa Thompson Gray, Srinivasan C. Krishnan, Aidong Qi, B. A. Brown, Olivier G. Boutaud, Darren W. Engers
+4 more Carrie K. Jones, Colleen Marie Niswender, Craig W. Lindsley, Aaron M. Bender
Cited by: 1
References: 60

Abstract

High Resolution Image Download MS PowerPoint Slide Herein, we report the identification of the HIV protease inhibitor amprenavir as a selective cannabinoid receptor 2 (CB 2 ) agonist and describe structure–activity relationship (SAR) studies toward repurposing this peripherally restricted scaffold for high CB 2 potency and CNS exposure. This exercise yielded compounds with exceptional CB 2 potency (EC 50 s 2 h), moderate plasma clearance, and appreciable brain exposure. Additionally, fully flexible protein–ligand docking studies with molecular dynamics (MD) simulations were used to predict the most likely mode of interaction of highly potent analogue VU6077967 with CB 2 and to provide a rationale for the observed selectivity of this series relative to CB 1 .

Fields of Study & Subjects

Cannabis and Cannabinoid Research Forensic Toxicology and Drug Analysis Psychedelics and Drug Studies

Publication details

Journal / source
Journal of Medicinal Chemistry
Publisher
American Chemical Society (ACS)
Volume
69
Issue
4
Pages
4187–4207
Publication date
5 February 2026
Language
EN